• Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy

  NCT03835520

  Active, not recruitingInterventionalNot ApplicableUpdated Dec 11, 2023
• Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma

  NCT02119559

  Unknown statusInterventionalNot ApplicableUpdated Dec 3, 2014
• Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis

  NCT06905145

  RecruitingObservationalUpdated Apr 1, 2025
• Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer

  NCT02572778

  RecruitingObservationalUpdated Dec 3, 2024
• ctDNA as a Biomarker for Treatment Response in HNSCC

  NCT03540563

  CompletedInterventionalNot ApplicableUpdated Feb 1, 2024
• Anti-tumor Specific Immune Response in Head and Neck Cancers

  NCT02881918

  Unknown statusObservationalUpdated Jan 26, 2018

ClinicalTrials.gov ID

NCT02139020

Lead Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

400Estimated

Last Update Posted

Dec 11, 2023Actual

Start Date

Feb 2013

Primary Completion Date

Jan 2033Estimated

Completion Date

Jan 2033Estimated

Official Title

Prospective Collection of Plasma Samples From Patients Treated With Molecular Targeted Therapies for Squamous Cell Carcinoma of the Head and Neck

Brief Summary

The investigators will collect plasma samples at baseline, during treatment, and at progression.

Detailed Description

In this study, the investigators will collect plasma samples at baseline, during treatment, and at progression. This plasma bank will be used to study the potential value of some biomarkers to predict treatment activity or resistance to cetuximab or other targeted agents

• Squamous Cell Carcinoma of the Head and Neck

• Plasma samples

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• patients treated with radiation therapy and cetuximab according to Bonner et al
• patients treated with cetuximab in combination with chemotherapy according to Vermorken et al.
• patients treated with a molecular targeted agent as a part of a clinical study

Exclusion Criteria:

• patients with another type of head and neck cancer
• patients non treated with targeted therapies

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER

brieuc.sautois@chuliege.be